Search results for "Computation"

showing 10 items of 7362 documents

Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes

2014

Abstract The determination of the epitope specificity of disease-associated T-cell responses is relevant for the development of biomarkers and targeted immunotherapies against cancer, autoimmune, and infectious diseases. The lack of known T-cell epitopes and corresponding T-cell receptors (TCR) for novel antigens hinders the efficient development and monitoring of new therapies. We developed an integrated approach for the systematic retrieval and functional characterization of TCRs from single antigen-reactive T cells that includes the identification of epitope specificity. This is accomplished through the rapid cloning of full-length TCR-α and TCR-β chains directly from single antigen-spec…

Cancer ResearchReceptors Antigen T-Cell/geneticsmedicine.medical_treatmentImmunologyReceptors Antigen T-CellEpitopes T-LymphocyteHistocompatibility Antigens Class I/immunologyComputational biologyBiologyEpitopeCell LineViral Matrix ProteinsMiceHistocompatibility Antigens Class II/immunologyAntigenAntigens NeoplasmT-Lymphocyte SubsetsmedicineAnimalsHumansViral Matrix Proteins/immunologyMembrane Proteins/geneticsCloning MolecularPhosphoproteins/immunologyAntigens Neoplasm/immunologyEpitopes T-Lymphocyte/immunologyHistocompatibility Antigens Class IT-cell receptorHistocompatibility Antigens Class IIPTEN PhosphohydrolasePTEN Phosphohydrolase/geneticsMembrane ProteinsRNAImmunotherapyPhosphoproteinsMolecular biologyT-Lymphocyte Subsets/immunologyIn vitroCell cultureCD8Protein BindingCancer Immunology Research
researchProduct

Regulon-Specific Control of Transcription Elongation across the Yeast Genome

2009

Transcription elongation by RNA polymerase II was often considered an invariant non-regulated process. However, genome-wide studies have shown that transcriptional pausing during elongation is a frequent phenomenon in tightly-regulated metazoan genes. Using a combination of ChIP-on-chip and genomic run-on approaches, we found that the proportion of transcriptionally active RNA polymerase II (active versus total) present throughout the yeast genome is characteristic of some functional gene classes, like those related to ribosomes and mitochondria. This proportion also responds to regulatory stimuli mediated by protein kinase A and, in relation to cytosolic ribosomal-protein genes, it is medi…

Cancer ResearchSaccharomyces cerevisiae Proteinslcsh:QH426-470Transcription GeneticComputational Biology/Transcriptional RegulationRNA polymerase IISaccharomyces cerevisiaeRegulonGenètica molecularSaccharomycesTranscripció genèticaTranscription (biology)GeneticsTranscriptional regulationMolecular BiologyRNA polymerase II holoenzymeGeneGenetics (clinical)Ecology Evolution Behavior and SystematicsGeneticsbiologyGenetics and Genomics/Functional GenomicsMolecular Biology/Transcription ElongationHigh Mobility Group ProteinsGenetics and Genomics/Gene ExpressionElongation factorDNA-Binding Proteinslcsh:GeneticsTAF4biology.proteinRNARNA Polymerase IITranscription factor II DGenome FungalTranscriptional Elongation FactorsBiochemistry/Transcription and TranslationResearch Article
researchProduct

OS1.5 Harnessing soluble LRIG1 for pan-RTK targeting in glioblastoma

2018

INTRODUCTION: The role of receptor tyrosine kinases (RTKs) in glioblastoma is widely acknowledged. However, therapies based on RTK targeting have been continuously unsuccessful in GBM patients, highlighting the complexity of RTK signaling and biology. LRIG1 (Leucine-rich Repeats and ImmunoGlobulin domains protein 1) was identified as an endogenous inhibitor of epidermal growth factor receptor (EGFR) and other RTKs, and was confirmed as a tumor suppressor in various cancer types. We previously identified the soluble form of LRIG1 as a potent inhibitor of GBM growth in vivo, irrespective of EGFR status. Here, we aim to shed light on the molecular mechanisms underlying its anti-cancer activity…

Cancer ResearchText miningOncologybusiness.industrymedicineOral PresentationsNeurology (clinical)Computational biologyBiologybusinessmedicine.diseaseGlioblastoma
researchProduct

Use of recombinant collagenases class I and II in optimization of cell purification for tissue engineering applications

2014

Cancer ResearchTransplantationClass (computer programming)ChemistryImmunologyCellCell BiologyComputational biologylaw.inventionmedicine.anatomical_structureOncologyTissue engineeringlawRecombinant DNACollagenasemedicineImmunology and Allergyrecombinant collagenases tissue engineering applicationsGenetics (clinical)medicine.drug
researchProduct

RNA-sequencing and bioinformatic analysis to pre-assess sensitivity to targeted therapeutics in recurrent glioblastoma.

2019

e13533 Background: This study developed molecular guided tools for individualized selection of chemotherapeutics for recurrent glioblastoma (rGB). A consortium involving clinical neurooncologists, molecular biologists and bioinformaticians identified gene expression patterns in rGB and quantitatively analyzed pathways involved in response to FDA approved oncodrugs. Methods: From2016 to 2018 biopsies from GB were collected using a multisampling approach. Biopsy material was used to isolate glioma stem-like cells and examined by RNA-sequencing. RNA-seq results were subjected to differential expression (DE) analysis and Oncobox analysis – a bioinformatic tool for quantitative pathway activati…

Cancer Researchbusiness.industryRecurrent glioblastomaRNAComputational biology03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisMedicineSensitivity (control systems)businessSelection (genetic algorithm)030215 immunologyJournal of Clinical Oncology
researchProduct

SuperHistopath: A Deep Learning Pipeline for Mapping Tumor Heterogeneity on Low-Resolution Whole-Slide Digital Histopathology Images.

2021

High computational cost associated with digital pathology image analysis approaches is a challenge towards their translation in routine pathology clinic. Here, we propose a computationally efficient framework (SuperHistopath), designed to map global context features reflecting the rich tumor morphological heterogeneity. SuperHistopath efficiently combines i) a segmentation approach using the linear iterative clustering (SLIC) superpixels algorithm applied directly on the whole-slide images at low resolution (5x magnification) to adhere to region boundaries and form homogeneous spatial units at tissue-level, followed by ii) classification of superpixels using a convolution neural network (CN…

Cancer Researchmedicine.medical_specialtyComputer scienceMagnificationContext (language use)lcsh:RC254-282Convolutional neural network030218 nuclear medicine & medical imaging03 medical and health sciencesneuroblastoma0302 clinical medicinebreast cancermedicinemelanomatumor region classificationSegmentationCluster analysisOriginal Researchbusiness.industryDeep learningDigital pathologydeep learningPattern recognitionlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmachine learningOncology030220 oncology & carcinogenesisHistopathologyArtificial intelligencebusinessdigital pathologycomputational pathologyFrontiers in oncology
researchProduct

Novel Approaches for Glioblastoma Treatment: Focus on Tumor Heterogeneity, Treatment Resistance, and Computational Tools

2019

BACKGROUND: Glioblastoma (GBM) is a highly aggressive primary brain tumor. Currently, the suggested line of action is the surgical resection followed by radiotherapy and treatment with the adjuvant temozolomide (TMZ), a DNA alkylating agent. However, the ability of tumor cells to deeply infiltrate the surrounding tissue makes complete resection quite impossible, and in consequence, the probability of tumor recurrence is high, and the prognosis is not positive. GBM is highly heterogeneous and adapts to treatment in most individuals. Nevertheless, these mechanisms of adaption are unknown. RECENT FINDINGS: In this review, we will discuss the recent discoveries in molecular and cellular heterog…

Cancer Researchmedicine.medical_treatmentDNA Mutational AnalysisBrain tumorBioinformaticsComplete resectionTumor heterogeneityCancer VaccinesMicrotubulesArticleClonal EvolutionMachine LearningGenetic HeterogeneityCancer stem cellAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineHumansTreatment resistancePrecision MedicineDNA Modification MethylasesImmune Checkpoint InhibitorsTemozolomideModels Geneticbusiness.industryBrain NeoplasmsTumor Suppressor ProteinsBrainComputational BiologyChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadiation therapyDNA Repair EnzymesOncologyDrug Resistance NeoplasmMutationTumor Suppressor Protein p53businessGlioblastomaGlioblastomamedicine.drug
researchProduct

Targeting cancer with peptide aptamers

2011

Renaud Seigneuric 1,2 , Jessica Gobbo 1,2 , Pierre Colas 3 , Carmen Garrido 1,2 1 Heat Shock Proteins and Cancer, INSERM, UMR 866 IFR 100, Faculty of Medicine, 7 Boulevard Jeanne D'Arc, 21000 Dijon, France 2 Universite de Bourgogne, Dijon, France 3 CNRS USR 3151, P2I2 Group, Station Biologique, Roscoff, Bretagne, France Received: June 22, 2011; Accepted: June 24, 2011; Published: June 24, 2011; Correspondence: Renaud Seigneuric, email: // // Abstract A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but al…

Cancer chemotherapyAptamermedicine.medical_treatmentRecombinant Fusion ProteinsPeptide Aptamersheat shock proteinAntineoplastic AgentsComputational biologyPharmacologyBiologyTargeted therapy03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansNanotechnologyMolecular Targeted TherapyHeat-Shock Proteins030304 developmental biologyCancer0303 health sciencesClinical Trials as TopicCanceraptamerAntineoplastic Protocolsmedicine.diseasetargeted therapypeptide3. Good healthOncology030220 oncology & carcinogenesisResearch PerspectivesAptamers PeptideOncotarget
researchProduct

Computational Methods for Gene Expression Profiling Using Next-Generation Sequencing (RNA-Seq)

2014

Cancer genome sequencingMassive parallel sequencingSingle cell sequencingComputational biologyBiologyBioinformaticsDeep sequencingExome sequencingDNA sequencingIllumina dye sequencingMassively parallel signature sequencing
researchProduct

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

2010

We undertook a meta-analysis of six Crohn's disease genome-wide association studies (GWAS) comprising 6,333 affected individuals (cases) and 15,056 controls and followed up the top association signals in 15,694 cases, 14,026 controls and 414 parent-offspring trios. We identified 30 new susceptibility loci meeting genome-wide significance (P < 5 x 10(-8)). A series of in silico analyses highlighted particular genes within these loci and, together with manual curation, implicated functionally interesting candidate genes including SMAD3, ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP. Combined with previously confirmed loci, these results identify 71 distinct loci with gen…

Candidate geneGenetic LinkagePROTEINGenome-wide association studyInflammatory bowel diseaseGenomeACTIVATION0302 clinical medicineCrohn DiseaseSEQUENCE VARIANTSGenetics0303 health sciencesGenomeNEDD4 FAMILYCOMMON VARIANTSASSOCIATION3. Good health030220 oncology & carcinogenesis10076 Center for Integrative Human PhysiologyComputational Biology; Crohn Disease; Genetic Linkage; Genetic Loci; Genetic Variation; Genome Human; Humans; Reproducibility of Results; Genetic Predisposition to Disease; Genome-Wide Association Study; Geneticsinflammatory-bowel-disease sequence variants common variants nedd4 family association gene identification receptor protein activationHuman/dk/atira/pure/subjectarea/asjc/1300/1311Locus (genetics)610 Medicine & healthBiology03 medical and health sciences1311 GeneticsGenetic linkagemedicineGeneticsHumansGenetic Predisposition to Disease030304 developmental biologyGenetic associationIDENTIFICATIONRECEPTORComputational BiologyGenetic VariationReproducibility of Resultsmedicine.diseaseGENESettore MED/03 - Genetica Medica10199 Clinic for Clinical Pharmacology and ToxicologyGenetic Loci570 Life sciences; biologyHuman genomegenome-wide scan.meta-analysis.crohn's diseaseGenome-Wide Association StudyINFLAMMATORY-BOWEL-DISEASE
researchProduct